Stephen J Fowler

List of Publications by Year
in descending order

153 papers	6,498 citations	66234 42 h-index	76769 74 g-index
154 all docs	154 docs citations	154 times ranked	7296 citing authors

#	Article	IF	Citations
1	Mapping atopic dermatitis and antiâ€“IL-22 response signatures to type 2â€“low severe neutrophilic asthma. Journal of Allergy and Clinical Immunology, 2022, 149, 89-101.	1.5	22
2	Untargeted Molecular Analysis of Exhaled Breath as a Diagnostic Test for Ventilator-Associated Lower Respiratory Tract Infections (BreathDx). Thorax, 2022, 77, 79-81.	2.7	10
3	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. European Respiratory Journal, 2022, 59, 2100768.	3.1	8
4	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. European Respiratory Journal, 2022, 59, 2100142.	3.1	10
5	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. European Respiratory Journal, 2022, 59, 2102603.	3.1	11
6	Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. European Respiratory Journal, 2022, 59, 2101733.	3.1	13
7	Differentiating Throat Symptoms in Inducible Laryngeal Obstruction From Anaphylaxisâ€”Information for Patients and Health Care Professionals. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 645-646.	2.0	3
8	Clinical and transcriptomic features of persistent exacerbationâ€prone severe asthma in Uâ€BIOPRED cohort. Clinical and Translational Medicine, 2022, 12, e816.	1.7	11
9	E-cigarette company tactics in sports advertising. Lancet Respiratory Medicine,the, 2022, 10, 634-636.	5.2	1
10	Exacerbation Profile and Risk Factors in a Type-2â€“Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 545-553.	2.5	14
11	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarkerâ€high and â€low severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2974-2986.	2.7	11
12	Systematic review of the effectiveness of non-pharmacological interventions used to treat adults with inducible laryngeal obstruction. BMJ Open Respiratory Research, 2022, 9, e001199.	1.2	2
13	Metabolic phenotyping of acquired ampicillin resistance using microbial volatiles from Escherichia coli cultures. Journal of Applied Microbiology, 2022, 133, 2445-2456.	1.4	3
14	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3362-3376.	2.7	7
15	Urinary Leukotriene E₄and Prostaglandin D₂Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 37-53.	2.5	49
16	Instability of sputum molecular phenotypes in U-BIOPRED severe asthma. European Respiratory Journal, 2021, 57, 2001836.	3.1	13
17	Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: A literature review. Clinical and Experimental Allergy, 2021, 51, 49-62.	1.4	16
18	Detection and quantification of exhaled volatile organic compounds in mechanically ventilated patients â€“ comparison of two sampling methods. Analyst, The, 2021, 146, 222-231.	1.7	8

#	Article	IF	Citations
19	Composite type-2 biomarker strategy versus a symptomâ€“risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 57-68.	5.2	88
20	Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma. Chronic Respiratory Disease, 2021, 18, 147997312110435.	1.0	11
21	Asthma diagnosis: into the fourth dimension. Thorax, 2021, 76, 624-631.	2.7	14
22	Same-day repeatability of fractional exhaled nitric oxide in severe asthma. European Respiratory Journal, 2021, 57, 2003391.	3.1	1
23	Can FeNO help guide firstâ€line treatment in suspected asthma?. Respirology, 2021, 26, 632-633.	1.3	1
24	Fungal asthma among Ugandan adult asthmatics. Medical Mycology, 2021, 59, 923-933.	0.3	10
25	Evaluation of an Aspergillus IgG/IgM lateral flow assay for serodiagnosis of fungal asthma in Uganda. PLoS ONE, 2021, 16, e0252553.	1.1	8
26	Serum Inhaled Corticosteroid Detection for Monitoring Adherence in Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4279-4287.e6.	2.0	6
27	Diagnosing Asthma with and without Aerosol-Generating Procedures. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4243-4251.e7.	2.0	7
28	Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. Chest, 2021, 160, 53-64.	0.4	10
29	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 731-734.	2.5	40
30	Prevalence of Aspergillus fumigatus skin positivity in adults without an apparent/known atopic disease in Uganda. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110390.	1.1	2
31	Soluble interleukin-2 receptor in exhaled breath condensate in pulmonary sarcoidosis: a cross-sectional pilot study. Journal of Breath Research, 2021, 15, 016016.	1.5	4
32	The peppermint breath test: a benchmarking protocol for breath sampling and analysis using GCâ€“MS. Journal of Breath Research, 2021, 15, 026006.	1.5	19
33	The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. ERJ Open Research, 2021, 7, 00768-2020.	1.1	14
34	Outcomes over the first two years of treatment with mepolizumab in severe asthma. European Respiratory Journal, 2021, 58, 2101313.	3.1	3
35	Breath and plasma metabolomics to assess inflammation in acute stroke. Scientific Reports, 2021, 11, 21949.	1.6	3
36	Reply to â€œTherapeutic drug monitoring of inhaled corticosteroids in exhaled breath for adherence assessmentâ€• Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4507-4508.	2.0	0

#	Article	IF	Citations
37	Exhaled volatile organic compounds as markers for medication use in asthma. European Respiratory Journal, 2020, 55, 1900544.	3.1	27
38	Development of a sensor device with polymer-coated piezoelectric micro-cantilevers for detection of volatile organic compounds. Measurement Science and Technology, 2020, 31, 035103.	1.4	7
39	Triggers of breathlessness in inducible laryngeal obstruction and asthma. Clinical and Experimental Allergy, 2020, 50, 1230-1237.	1.4	15
40	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. Journal of Allergy and Clinical Immunology, 2020, 146, 1045-1055.	1.5	22
41	Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA). Health and Quality of Life Outcomes, 2020, 18, 336.	1.0	10
42	UK consensus statement on the diagnosis of inducible laryngeal obstruction in light of the COVIDâ€19 pandemic. Clinical and Experimental Allergy, 2020, 50, 1287-1293.	1.4	6
43	Volatile organic compounds associated with diagnosis and disease characteristics in asthma â€“ A systematic review. Respiratory Medicine, 2020, 169, 105984.	1.3	25
44	Treating asthma in the COVID-19 pandemic. Thorax, 2020, 75, 822-823.	2.7	11
45	Effects of high relative humidity and dry purging on VOCs obtained during breath sampling on common sorbent tubes. Journal of Breath Research, 2020, 14, 046006.	1.5	23
46	Effectiveness of myAirCoach: A mHealth Self-Management System in Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1972-1979.e8.	2.0	42
47	Exerciseâ€induced bronchoconstriction: A survey of diagnostic practice in secondary care across the United Kingdom. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2130-2132.	2.7	2
48	Clinical phenotyping. , 2020, , 321-334.		1
49	A benchmarking protocol for breath analysis: the peppermint experiment. Journal of Breath Research, 2020, 14, 046008.	1.5	41
50	Understanding antimicrobial prescribing in suspected ventilator-associated pneumonia: a prospective cohort study. Access Microbiology, 2020, 2, .	0.2	0
51	Exhaled breath testing â€“ A tool for the clinician and researcher. Paediatric Respiratory Reviews, 2019, 29, 37-41.	1.2	48
52	Asthma Diagnosis: The Changing Face of Guidelines. Pulmonary Therapy, 2019, 5, 103-115.	1.1	18
53	Pseudomonas aeruginosa-Derived Volatile Sulfur Compounds Promote Distal Aspergillus fumigatus Growth and a Synergistic Pathogen-Pathogen Interaction That Increases Pathogenicity in Co-infection. Frontiers in Microbiology, 2019, 10, 2311.	1.5	39
54	Contribution of airway eosinophils in airway wall remodeling in asthma: Role of <scp>MMP</scp>â€10 and <scp>MET</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1102-1112.	2.7	32

#	Article	IF	Citations
55	Stratification of asthma phenotypes by airway proteomic signatures. Journal of Allergy and Clinical Immunology, 2019, 144, 70-82.	1.5	59
56	Circadian rhythm of exhaled biomarkers in health and asthma. European Respiratory Journal, 2019, 54, 1901068.	3.1	37
57	IL-17â€“high asthma with features of a psoriasis immunophenotype. Journal of Allergy and Clinical Immunology, 2019, 144, 1198-1213.	1.5	80
58	Burden of fungal asthma in Africa: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0216568.	1.1	43
59	Sex and intimacy in people with severe asthma: a qualitative study. BMJ Open Respiratory Research, 2019, 6, e000382.	1.2	5
60	Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux. European Respiratory Journal, 2019, 53, 1900453.	3.1	15
61	The role of measuring exhaled breath biomarkers in sarcoidosis: a systematic review. Journal of Breath Research, 2019, 13, 036015.	1.5	11
62	Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma. Journal of Allergy and Clinical Immunology, 2019, 144, 788-795.e1.	1.5	37
63	Investigating the safety of capsaicin cough challenge in severe asthma. Clinical and Experimental Allergy, 2019, 49, 932-934.	1.4	11
64	Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. Respiratory Medicine, 2019, 150, 66-73.	1.3	19
65	Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 823-829.	2.5	31
66	Heliox for inducible laryngeal obstruction (vocal cord dysfunction): A systematic literature review. Laryngoscope Investigative Otolaryngology, 2019, 4, 255-258.	0.6	10
67	Exhaled breath metabolomics reveals a pathogen-specific response in a rat pneumonia model for two human pathogenic bacteria: a proof-of-concept study. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L751-L756.	1.3	17
68	Breath biomarkers in asthma: we're getting answers, but what are the important questions?. European Respiratory Journal, 2019, 54, 1901411.	3.1	4
69	Capturing and Storing Exhaled Breath for Offline Analysis. , 2019, , 13-31.		10
70	Identification and prospective stability of electronic nose (eNose)â€“derived inflammatory phenotypes in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 1811-1820.e7.	1.5	74
71	Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. Respiratory Research, 2019, 20, 7.	1.4	25
72	Treatable traits in the European Uâ€<scp>BIOPRED</scp> adult asthma cohorts. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 406-411.	2.7	37

#	Article	IF	Citations
73	Methodological considerations for large-scale breath analysis studies: lessons from the U-BIOPRED severe asthma project. Journal of Breath Research, 2019, 13, 016001.	1.5	20
74	Clinical biomarkers and noninvasive assessment of severe asthma. , 2019, , 93-112.		2
75	Clinical presentation, assessment, and management of inducible laryngeal obstruction. Current Opinion in Otolaryngology and Head and Neck Surgery, 2018, 26, 174-179.	0.8	19
76	Reclassification of Bronchodilator Reversibility in the U-BIOPRED Adult Asthma Cohort Using zÂScores. Chest, 2018, 153, 1070-1072.	0.4	7
77	Breath analysis for label-free characterisation of airways disease. European Respiratory Journal, 2018, 51, 1702586.	3.1	6
78	The potential role of exhaled breath analysis in the diagnostic process of pneumoniaâ€"a systematic review. Journal of Breath Research, 2018, 12, 024001.	1.5	56
79	Two pathways, one patient; UK asthma guidelines. Thorax, 2018, 73, 797-798.	2.7	6
80	Peripheral Interventions for Painful Stump Neuromas of the Lower Limb. Clinical Journal of Pain, 2018, 34, 285-295.	0.8	12
81	Headspace volatile organic compounds from bacteria implicated in ventilator-associated pneumonia analysed by TD-GC/MS. Journal of Breath Research, 2018, 12, 026002.	1.5	33
82	Pathway discovery using transcriptomic profiles in adult-onset severe asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 1280-1290.	1.5	105
83	Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers. Metabolomics, 2018, 14, 123.	1.4	17
84	Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. PLoS ONE, 2018, 13, e0203874.	1.1	18
85	Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1578-1581.	2.5	53
86	Development of an adaptable headspace sampling method for metabolic profiling of the fungal volatome. Analyst, The, 2018, 143, 4155-4162.	1.7	22
87	A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. Trials, 2018, 19, 5.	0.7	26
88	TD/GCâ€"MS analysis of volatile markers emitted from mono- and co-cultures of Enterobacter cloacae and Pseudomonas aeruginosa in artificial sputum. Metabolomics, 2018, 14, 66.	1.4	26
89	Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome. Journal of Proteome Research, 2018, 17, 2072-2091.	1.8	16
90	Volatile organic compound signature from co-culture of lung epithelial cell line with Pseudomonas aeruginosa. Analyst, The, 2018, 143, 3148-3155.	1.7	28

#	Article	IF	Citations
91	Biomarkers in adult asthma: a systematic review of 8-isoprostane in exhaled breath condensate. Journal of Breath Research, 2017, 11, 016011.	1.5	16
92	BreathDx â€“ molecular analysis of exhaled breath as a diagnostic test for ventilatorâ€“associated pneumonia: protocol for a European multicentre observational study. BMC Pulmonary Medicine, 2017, 17, 1.	0.8	84
93	Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax, 2017, 72, 129-136.	2.7	130
94	MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational study. BMJ Open, 2017, 7, e013935.	0.8	51
95	The interaction between bronchoconstriction and cough in asthma. Thorax, 2017, 72, 1144-1146.	2.7	29
96	Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 1144-1146.e4.	1.5	42
97	Perspectives of patients and healthcare professionals on mHealth for asthma self-management. European Respiratory Journal, 2017, 49, 1601966.	3.1	61
98	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. European Respiratory Journal, 2017, 49, 1600965.	3.1	432
99	Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. European Respiratory Journal, 2017, 50, 1602298.	3.1	44
100	Exhaled breath analysis: a review of â€˜breath-takingâ€™ methods for off-line analysis. Metabolomics, 2017, 13, 110.	1.4	178
101	Exhaled Volatile Organic Compounds of Infection: A Systematic Review. ACS Infectious Diseases, 2017, 3, 695-710.	1.8	96
102	Assessing machine learning algorithms for self-management of asthma. , 2017, , .		9
103	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. Journal of Allergy and Clinical Immunology, 2017, 139, 1797-1807.	1.5	236
104	A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 443-455.	2.5	165
105	A pilot study to investigate the use of serum inhaled corticosteroid concentration as a potential marker of treatment adherence in severe asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1037-1039.e1.	1.5	9
106	Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction. Journal of Allergy and Clinical Immunology, 2017, 139, 771-779.e10.	1.5	72
107	An airway traffic jam: a plastic traffic cone masquerading as bronchial carcinoma. BMJ Case Reports, 2017, 2017, bcr-2017-220514.	0.2	0
108	Reduction in peripheral blood eosinophil counts after bronchial thermoplasty. Journal of Allergy and Clinical Immunology, 2016, 138, 308-310.e2.	1.5	15

#	Article	IF	Citations
109	Dysfunctional breathing: a review of the literature and proposal for classification. European Respiratory Review, 2016, 25, 287-294.	3.0	217
110	Breathomics in the setting of asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2016, 138, 970-976.	1.5	88
111	Laryngeal Dysfunction: Assessment and Management for the Clinician. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1062-1072.	2.5	78
112	Electronic cigarette exposure triggers neutrophil inflammatory responses. Respiratory Research, 2016, 17, 56.	1.4	117
113	Fungal sensitisation in severe asthma is associated with the identification of Aspergillus fumigatus in sputum. Journal of Asthma, 2016, 53, 732-735.	0.9	34
114	Objective Cough Frequency, Airway Inflammation, and Disease Control in Asthma. Chest, 2016, 149, 1460-1466.	0.4	49
115	Interventions for bronchiectasis: an overview of Cochrane systematic reviews. The Cochrane Library, 2015, 2015, CD010337.	1.5	56
116	The <scp>VCDQ</scp> â€“ a Questionnaire for symptom monitoring in vocal cord dysfunction. Clinical and Experimental Allergy, 2015, 45, 1406-1411.	1.4	69
117	High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2015, 135, 822-824.e2.	1.5	89
118	Surveillance for lower airway pathogens in mechanically ventilated patients by metabolomic analysis of exhaled breath: a case-control study. Thorax, 2015, 70, 320-325.	2.7	54
119	Refractory asthma â€“ beyond step 5, the role of new and emerging adjuvant therapies. Chronic Respiratory Disease, 2015, 12, 69-77.	1.0	14
120	Detecting laryngopharyngeal reflux in patients with upper airways symptoms: Symptoms, signs or salivary pepsin?. Respiratory Medicine, 2015, 109, 963-969.	1.3	56
121	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. European Respiratory Journal, 2015, 46, 1308-1321.	3.1	434
122	The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. European Respiratory Journal, 2015, 46, 1322-1333.	3.1	179
123	Chemometrics models for overcoming high between subject variability: applications in clinical metabolic profiling studies. Metabolomics, 2014, 10, 375-385.	1.4	12
124	Taking your breath away: metabolomics breathes life in to personalized medicine. Trends in Biotechnology, 2014, 32, 538-548.	4.9	132
125	Inhaled hyperosmolar agents for bronchiectasis. The Cochrane Library, 2014, 2014, CD002996.	1.5	32
126	Breath metabolomic profiling by nuclear magnetic resonance spectroscopy in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1050-1056.	2.7	46

#	Article	IF	Citations
127	Application of â€™omics technologies to biomarker discovery in inflammatory lung diseases. European Respiratory Journal, 2013, 42, 802-825.	3.1	234
128	Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respiratory Research, 2012, 13, 72.	1.4	80
129	Methodology validation, intra-subject reproducibility and stability of exhaled volatile organic compounds. Journal of Breath Research, 2012, 6, 026002.	1.5	22
130	Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax, 2011, 66, 804-809.	2.7	173
131	Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst, The, 2010, 135, 315.	1.7	119
132	Long-Term Effects of Allergen Sensitization and Exposure in Adult Asthma. World Allergy Organization Journal, 2009, 2, 83-90.	1.6	5
133	Increasing analytical space in gas chromatography-differential mobility spectrometry with dispersion field amplitude programming. Journal of Chromatography A, 2007, 1173, 129-138.	1.8	13
134	Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. European Respiratory Journal, 2006, 28, 1204-1210.	3.1	145
135	Relationship of skin-prick reactivity to aeroallergens and hyperresponsiveness to challenges with methacholine and adenosine monophosphate. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 46-52.	2.7	25
136	Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting. Allergology International, 2003, 52, 71-75.	1.4	0
137	A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. British Journal of Clinical Pharmacology, 2003, 55, 609-615.	1.1	13
138	Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clinical and Experimental Allergy, 2003, 33, 783-788.	1.4	53
139	Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Annals of Allergy, Asthma and Immunology, 2003, 90, 194-198.	0.5	62
140	Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax, 2002, 57, 865-868.	2.7	15
141	Therapeutic Ratio of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Fluticasone Propionate. Chest, 2002, 122, 618-623.	0.4	24
142	Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma. Chest, 2002, 122, 151-159.	0.4	40
143	Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134aâ€“beclomethasone alone. Journal of Allergy and Clinical Immunology, 2002, 109, 929-935.	1.5	46
144	5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. European Journal of Clinical Pharmacology, 2002, 58, 187-190.	0.8	35

#	Article	IF	Citations
145	On-demand relief treatment for asthma. Lancet, The, 2001, 357, 1882.	6.3	1
146	Montelukast for persistent asthma. Lancet, The, 2001, 358, 1455.	6.3	2
147	Pharmacokinetics and systemic Î²2 -adrenoceptor-mediated responses to inhaled salbutamol. British Journal of Clinical Pharmacology, 2001, 51, 359-362.	1.1	25
148	Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. British Journal of Clinical Pharmacology, 2001, 52, 93-95.	1.1	25
149	Comparative In Vivo Lung Delivery of Hydrofluoroalkane-Salbutamol Formulation Via Metered-Dose Inhaler Alone, With Plastic Spacer, or With Cardboard Tube. Chest, 2001, 119, 1018-1020.	0.4	9
150	Regular use of salbutamol in asthma. Lancet, The, 2000, 356, 853.	6.3	0
151	Fluticasone propionate bioavailability in asthma. Lancet, The, 2000, 356, 1681.	6.3	2
152	Screening for Bronchial Hyperresponsiveness Using Methacholine and Adenosine Monophosphate. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1318-1322.	2.5	82
153	Short- and medium-term effect of inhaled corticosteroids on exhaled breath biomarkers in severe asthma. Journal of Breath Research, 0, , .	1.5	1